Key market opportunities in the shingles vaccine sector include rising elderly populations; expanding healthcare ...

MRNA is likely to have faced earnings pressure and pipeline setbacks as waning COVID-19 vaccine demand weighs on its outlook.

The decades-long quest to harness the power of messenger RNA to enhance cancer treatment has focused primarily on its value ...

The start of the trial marks an expansion of the firm's oncology pipeline, and the firm hopes mRNA-2808 will be the first of many T-cell engagers in its portfolio.

Yale researchers have developed a new vaccine that does double duty against a rare and aggressive skin cancer by targeting ...